Chronic pain treatment options
Every major approach compared — mechanisms, evidence strength, and who each fits.
Wanting off opioids — or wanting never to start — isn't settling for less. For most chronic pain, the non-opioid path is the one with better long-term evidence.
How can chronic pain be treated without opioids?
Chronic pain can be treated effectively without opioids — often more effectively. First-line options include graded exercise and physical therapy, pain neuroscience education, and psychological therapies like CBT and pain reprocessing therapy, plus newer VR-based retraining. Non-opioid medications (NSAIDs, SNRIs, tricyclics, gabapentinoids) help specific pain mechanisms. The CDC's 2022 guideline states these approaches are preferred for most chronic pain, because long-term opioids show limited benefit and accumulating risk.
If you're currently taking opioids, none of this means stopping on your own — tapering is a gradual, physician-guided process, and abrupt changes can be dangerous.
Opioids are genuinely effective for acute pain, surgical recovery, and cancer and end-of-life care. The problem is specifically long-term use for chronic non-cancer pain, where three biological realities work against them.
The trial evidence matches the biology: studies of long-term opioid therapy for chronic back, hip, and knee pain have found small average improvements at best — and in one prominent year-long randomized trial, opioids performed no better than non-opioid medication for pain-related function. Meanwhile the risks (sedation, falls, hormonal effects, overdose) accumulate with dose and time.
This is why the CDC's 2022 Clinical Practice Guideline states that non-opioid therapies are preferred for most chronic pain. Notably, the same guideline is emphatic that people already taking opioids should never be force-tapered or abandoned — the goal is better pain care, not less care.
Non-opioid doesn't mean weaker — it means differently targeted. Each class below works on a specific mechanism, which is why the right pick depends on whether your pain is inflammatory, neuropathic, or neuroplastic. All of these are decisions to make with your prescriber.
| Class | Examples | Best for | Worth knowing |
|---|---|---|---|
| NSAIDs | Ibuprofen, naproxen | Inflammatory pain and flare-ups | Effective short-term; daily long-term use carries stomach, kidney, and heart risks |
| SNRIs | Duloxetine | Fibromyalgia, neuropathic pain, chronic musculoskeletal pain | Works on the body's pain-modulation pathways — prescribed for pain, not just mood |
| Tricyclics | Amitriptyline, nortriptyline | Nerve pain, pain with disrupted sleep | Used at low doses for decades; drowsiness and dry mouth are the common trade-offs |
| Gabapentinoids | Gabapentin, pregabalin | Defined neuropathic pain (e.g., post-shingles, diabetic neuropathy) | Weak evidence for ordinary back pain, where they are frequently overprescribed |
| Topicals | Lidocaine, capsaicin, topical NSAIDs | Localized pain near the surface | Minimal systemic risk, so often worth trying early for focal pain |
A realistic framing helps: for chronic pain, medications typically take the edge off rather than switch the pain off. Their best use is making the active treatments below easier to do — the treatments that actually change the trajectory. See the full treatment landscape for how they fit together.
The strongest evidence in chronic pain care belongs to non-drug, active treatments — the ones that retrain the pain system rather than muffling its output.
The pattern across the evidence: passive treatments (pills, needles, hands-on relief) fade when they stop; active treatments (movement, education, retraining) keep paying off after they end — because they change the system that produces the pain.
Everyday supports matter too — sleep, stress load, pacing, and flare planning all feed the pain system's sensitivity. Our guide to living with chronic pain covers the day-to-day toolkit.
If you're taking opioids and want to reduce or stop, the single most important principle is: never abruptly, and never alone. Stopping suddenly can cause severe withdrawal, spikes in pain and blood pressure, and — because tolerance fades quickly — a dangerous overdose risk if doses resume. Tapering is a medical process that belongs in your prescriber's hands.
This page deliberately gives principles, not schedules — the right pace depends on your dose, how long you've taken it, your health, and how you respond, which only your prescriber can assess.
Many people find their pain is no worse — and sometimes better — at lower doses or off opioids entirely, particularly once hyperalgesia unwinds and active retraining takes hold.
A workable plan layers a few things rather than betting on one. A common shape:
This layered, retrain-first approach is exactly what structured programs deliver. Karuna's program is drug-free by design — physician oversight, VR embodiment training, and 1:1 coaching over 12 weeks from home, HSA/FSA eligible, with a money-back guarantee. If you're weighing options, reach out or browse the conditions we work with.
It depends on your pain mechanism, but across chronic pain conditions the largest and most durable effects come from active treatments: graded exercise, pain neuroscience education, and retraining therapies like pain reprocessing therapy and skills-based VR. Among medications, SNRIs like duloxetine have solid evidence for fibromyalgia and musculoskeletal pain, and gabapentinoids for defined nerve pain — but no pill matches the long-term evidence of active retraining.
For many people, yes. The treatments with the strongest evidence — movement, education, psychological retraining, and VR-based training — involve no drugs. In the Boulder trial of pain reprocessing therapy, two-thirds of participants became pain-free or nearly so with no new medication. Others do best with a targeted non-opioid medication as a support. Both are legitimate versions of success.
The CDC's 2022 Clinical Practice Guideline says non-opioid therapies are preferred for most chronic pain, and that when opioids are used, clinicians should start at the lowest effective dose and weigh benefits against risks regularly. Just as importantly, it warns against abrupt discontinuation and rigid dose cutoffs for people already on opioids — tapering should be gradual, collaborative, and never forced.
Yes — don't do it. Abrupt discontinuation after long-term use can cause severe withdrawal, surging pain, and psychological distress, and because tolerance fades within days, returning to a previous dose afterward carries real overdose risk. Any reduction should be a gradual taper planned with your prescriber, who can adjust the pace as you go.
Often less than feared. Temporary increases during a taper are common and usually settle as the nervous system recalibrates. Studies of slow, supported tapers find that many people report pain that is unchanged — or improved — at lower doses, partly because opioid-induced hyperalgesia unwinds. Pairing the taper with active treatment like graded movement and VR retraining improves the odds considerably.
They can help, modestly, and they're low-risk — which earns them a place as adjuncts. Trials show small-to-moderate short-term benefits for some conditions. The caution is strategic, not dismissive: as passive treatments, their effects tend to fade between sessions, so they work best supporting an active plan of movement and retraining rather than replacing one.
Yes. The 12-week program uses VR embodiment training, physician oversight, and 1:1 pain coaching — no medications are prescribed as part of it, and it never asks you to change existing medications on your own. Any adjustments to what you currently take remain between you and your prescriber. See how it works for the full structure.
Talk with our care team about your pain, your history, and whether KVET™ is right for you — free, and from the comfort of home.